Angiotensin 1/2 (2-7): Precision Peptide for Hypertension and RAS Research

Executive Summary:
Angiotensin 1/2 (2-7) (sequence: ARG-VAL-TYR-ILE-HIS-PRO) is a peptide fragment derived from angiotensin I and II via enzymatic processing in the renin-angiotensin system (RAS) (APExBIO product page). This peptide plays a critical role in blood pressure regulation and vasoconstriction by stimulating aldosterone release and promoting sodium retention (Oliveira et al., 2025). Angiotensin 1/2 (2-7) exhibits high purity (99.80% by HPLC/MS) and robust solubility in water, ethanol, and DMSO under specified conditions. Recent research demonstrates that N-terminal angiotensin fragments, including (2-7), modulate interactions with viral spike proteins, impacting infectious disease models. The product is intended strictly for scientific research; it is not for diagnostic or therapeutic use.

Biological Rationale

Angiotensin 1/2 (2-7) is an endogenous peptide produced via cleavage of angiotensin I and II in the RAS (Oliveira et al., 2025). It specifically comprises amino acids 2 through 7 of the angiotensin I/II sequence: ARG-VAL-TYR-ILE-HIS-PRO. The renin-angiotensin system regulates cardiovascular and renal physiology, with angiotensin peptides serving as mediators of vasoconstriction and sodium homeostasis. Angiotensin 1/2 (2-7) and related fragments contribute to the fine-tuning of blood pressure and volume through receptor-mediated mechanisms, including AT1R and AT2R signaling. This peptide's influence extends to aldosterone secretion and distal nephron sodium retention. Recent work suggests that shorter angiotensin fragments may have distinct activities from their parent peptides, with implications for both cardiovascular and infectious disease research (DOI:10.3390/ijms26136067).

Mechanism of Action of Angiotensin 1/2 (2-7)

Angiotensin 1/2 (2-7) is generated by proteolytic cleavage from angiotensin I (1–10) and angiotensin II (1–8) through the action of renin and angiotensin-converting enzyme (ACE) (Oliveira et al., 2025). The specific sequence of Angiotensin 1/2 (2-7) enables it to interact with receptors and effector pathways distinct from longer angiotensin peptides. It contributes to vasoconstriction by stimulating aldosterone release from the adrenal cortex, thereby increasing sodium reabsorption in the distal nephron and promoting fluid retention (APExBIO). In addition, N-terminally truncated peptides, including 2–7, have been shown to potentiate spike–AXL binding in viral pathogenesis models, highlighting their role in modulating host-pathogen interactions (Oliveira et al., 2025).

Evidence & Benchmarks

• Angiotensin 1/2 (2-7) is generated through enzymatic cleavage of angiotensin I and II in the RAS pathway (DOI:10.3390/ijms26136067).
• This peptide fragment stimulates aldosterone release and enhances sodium retention, contributing to elevated blood pressure (DOI:10.3390/ijms26136067).
• In antibody-based binding assays, N-terminal deletions such as Angiotensin 1/2 (2-7) displayed enhanced ability to promote spike–AXL binding compared to longer angiotensin peptides (DOI:10.3390/ijms26136067).
• Angiotensin 1/2 (2-7) has a molecular weight of 783.92 Da and a chemical formula of C37H57N11O8 as confirmed by HPLC and mass spectrometry (APExBIO).
• Solubility benchmarks: ≥2.78 mg/mL in ethanol, ≥46.6 mg/mL in water, and ≥78.4 mg/mL in DMSO at room temperature (20–25°C) (APExBIO).
• Short-term solution stability is optimal at -20°C; repeated freeze-thaw cycles are discouraged (APExBIO).
• Compared to angiotensin I (1-10), N-terminal truncated peptides (including 2-7) show increased spike–AXL binding effect (up to 2.7-fold with similar analogs) (DOI:10.3390/ijms26136067).

Related Reading: For detailed mechanistic analysis, see "Angiotensin 1/2 (2-7): Mechanistic Insights and Strategic...", which provides foundational context. This article extends those findings by focusing on recent peptide-virus interaction evidence and experimental benchmarks.

Applications, Limits & Misconceptions

Angiotensin 1/2 (2-7) is a research reagent for hypertension, cardiovascular disease, and viral pathogenesis models. It supports mechanistic studies in the renin-angiotensin signaling pathway, including receptor binding, peptide processing, and downstream physiological effects. The product is intended for use in vitro, ex vivo, and in select in vivo studies under controlled conditions. Its robust solubility and high purity facilitate reproducibility in experimental workflows.

For nuanced discussion of translational applications, see "Angiotensin 1/2 (2-7): Novel Peptide Tools for RAS Pathwa..."—this article updates prior content by including SARS-CoV-2 spike protein binding data.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (2-7) is not intended for diagnostic or clinical therapeutic use; it is strictly for research applications (APExBIO).
• It should not be used as a substitute for full-length angiotensin peptides in physiological modeling unless specifically justified by the research question.
• Peptide solutions are unstable at room temperature for extended periods; improper storage can result in degradation and loss of activity.
• Interpretation of viral pathogenesis findings requires context: spike–AXL binding enhancement may not extrapolate directly to in vivo infectivity.
• Batch-to-batch consistency must be confirmed by HPLC/MS for reproducible results.

Workflow Integration & Parameters

Angiotensin 1/2 (2-7) is supplied as a solid by APExBIO (SKU: A1050) and should be reconstituted in water, ethanol, or DMSO according to solubility parameters (≥46.6 mg/mL in water recommended for most applications). For optimal stability, store lyophilized material at -20°C and minimize freeze-thaw cycles. Prepare working solutions fresh and use within hours to days depending on buffer and application. Analytical verification by HPLC or MS is recommended upon receipt and after reconstitution. For cardiovascular or viral receptor studies, dosing should be benchmarked against published concentrations (see Oliveira et al., 2025 for reference binding assays).

For advanced integration strategies and a comparison of peptide toolkits, refer to "Angiotensin 1/2 (2-7): Precision Tools for Next-Generatio...". This article supplements prior guidance by providing detailed experimental parameters and stability data.

Conclusion & Outlook

Angiotensin 1/2 (2-7) is a rigorously validated renin-angiotensin system peptide with high purity and robust solubility, suitable for mechanistic, translational, and disease modeling research. Its unique N-terminal structure confers distinct receptor interactions and functional properties, including modulation of viral spike protein binding. The product's design and quality control parameters make it a benchmark tool for cardiovascular and infectious disease studies. Future research may further delineate its therapeutic and mechanistic potential, but current use is limited to non-clinical investigations. For further technical details or ordering, see the Angiotensin 1/2 (2-7) product page.